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Update: Rural/Urban Disparities in Pneumococcal Vaccine Service Delivery 
Among the Fee-for-Service Medicare Population, 2012-2015 
Joseph Vanghelof, PharmD, MS; Aric Schadler, MS; Patricia R. Freeman, PhD; and Jeffery Talbert, PhD 
Overview of Key Findings 
▪ Between 2014 and 2015, the number of pneumococcal vaccine services delivered to fee-for-service 
(FFS) Medicare beneficiaries increased by 380% as a result of uptake of PCV13 vaccine. 
▪ Continued disparities in delivery of pneumococcal vaccine services to FFS Medicare beneficiaries in 
rural and urban communities are noted, with a 63% higher vaccination rate observed in urban areas. 
▪ The majority of pneumococcal vaccine services delivered to FFS Medicare beneficiaries were 
provided by primary care providers, although pharmacy providers delivered close to one-fourth 
(24.2%) of these services. 
▪ Pharmacy providers in rural communities play an increasing role in pneumococcal vaccine service 
delivery, providing one-third (33.5%) of vaccines in 2015.  
Purpose 
This Policy Brief is the second report from the Rural and Underserved Health Research Center assessing 
rural/urban disparities in pneumococcal vaccine service delivery among the fee-for-service (FFS) Medicare 
population. This report is an update of the initial report1 and was conducted to specifically assess uptake of the 
13-valent pneumococcal conjugate vaccine (PCV13) following revised vaccination recommendations released 
in 2014. 
Introduction  
Pneumococcal disease remains a significant public health concern in the U.S., especially for older adults where 
mortality from invasive pneumococcal disease (IPD) ranges from 20% at age 65 to 40% at age 85.2 Current 
recommendations from the Advisory Committee on Immunization Practices (ACIP), in place since September 
2014, call for all persons age 65 and older to be vaccinated with a 2-dose vaccination series; 1 dose PCV13 at 
age 65 and 1 dose 23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 1 year later.3 The 
previous recommendation for persons age 65 and older was to receive 1 dose of PPSV23, with PCV13 reserved 
for those considered high risk. Recommendation for the 2-dose series was made following evidence showing 
that up to 25% of IPD and 10% of community acquired pneumonia in older adults are caused by PCV13 
vaccine serotypes.4 Despite these recommendations, vaccination rates remain low for either vaccine 
individually (<50%) and for the complete 2-dose series (<20%), with racial and geographic disparities in 
pneumococcal vaccination uptake noted.4 
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In a previous RUHRC report assessing pneumococcal vaccine service delivery in the FFS Medicare population, 
we documented a significant disparity in pneumococcal vaccination rates between rural and urban areas across 
the nation, with a 40% lower mean vaccination rate observed in rural communities in 2014.1 Overall, 
pneumococcal vaccination service rates were low and varied considerably by state. Although primary care 
providers delivered a majority of pneumococcal vaccine services to adults age 65 and older in the Medicare 
FFS population, a significantly greater proportion of pneumococcal vaccine services was delivered by 
pharmacy providers in rural areas, and regression models indicated that pharmacy providers had a significant 
impact on pneumococcal vaccine delivery in rural areas.   
Our previous report evaluated overall pneumococcal vaccination service delivery in the year 2014, without 
assessing the contribution of the individual pneumococcal vaccines (PCV13 and PPSV23). The objective of 
this study was to evaluate trends in pneumococcal vaccination service delivery for the years 2012 through 
2015, and to specifically assess uptake of the PCV13 in 2015, the first full year following the revised 
vaccination recommendations in September 2014. A secondary objective was to determine the relative 
contribution of community pharmacies as an alternate site vaccine service provider to PCV13 uptake in rural 
communities.  
Methods 
Vaccination service data were obtained from the Medicare Physician and Other Supplier Public Use File, which 
reports the services and number of FFS beneficiaries treated by physicians and other providers.5 Services were 
restricted to the following: administration of any pneumococcal vaccine via Healthcare Common Procedure 
Coding System (HCPCS) G0009, PCV13 administration via Current Procedural Terminology (CPT) 90670, 
and PPSV23 administration via CPT 90732. Providers were classified as either: 1) primary care provider (e.g., 
nurses, physician assistants, and family practice physicians); 2) pharmacy provider; or 3) other providers (e.g., 
physician specialists). Provider county was estimated using provider zip code, then linked to Rural-Urban 
Continuum Codes (RUCC) and the Medicare Geographic Variation State/County table Public Use File. RUCC 
classifies counties on a scale of 1 to 9, with 1-3 designated as urban, and 4-9 as rural.6 The Medicare 
Geographic Variation table reports for each county: the number of FFS enrollees; average age; average 
Hierarchical Condition Category (HCC) score, a composite risk score reflective of chronic disease burden; and 
percent male, white non-Hispanic, eligible for Medicaid, and using inpatient or outpatient services.7 
Descriptive statistics on vaccine services by rural-urban designation, provider type, vaccine type, and year were 
calculated. A logistic regression model of the estimated rate of pneumococcal vaccination in 2015 was created 
using the parameters from the Medicare Geographic Variation table, rural-urban designation, the percent of 
vaccines provided by pharmacists, and the interaction of rural-urban designation with percent of vaccines 
provided by pharmacists.  
Findings 
The number and rate of pneumococcal vaccination services delivered by FFS Medicare providers to eligible 
beneficiaries increased annually between 2012 and 2015. In 2015, pneumococcal vaccine services were 
delivered by providers to approximately 5,353,000 FFS beneficiaries representing 16% of the FFS population 
nationwide, a 380% increase over that reported in 2014.1 Consistent with our previous findings, continued 
disparities in pneumococcal vaccine service delivery are noted between rural and urban communities with an 
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estimated 10.7% of FFS beneficiaries receiving 
pneumococcal vaccination services in rural communities 
compared to 17.4% in urban communities, signifying a 
63% higher vaccination rate in urban communities.  
Prior to 2015, the vast majority of pneumococcal vaccine 
services provided were for PPSV23, as expected based on 
ACIP recommendations for adults 65 and older (Table 1). 
In 2015, following the revised recommendations for the 2-
dose vaccination series with PCV13 followed by PPSV23 
at least 1 year later, PCV13 comprised over 90% of all pneumococcal vaccine services. The increase in the rate 
of pneumococcal vaccination service delivery noted in 2015 was driven by uptake in the rate of PCV13 
vaccination services. 
As shown in Table 2, in 2015, primary 
care providers delivered the majority 
(72.2%) of pneumococcal vaccination 
services to FFS Medicare beneficiaries 
while pharmacy providers accounted 
for one-fourth. In rural communities, 
pharmacy providers delivered one-third 
of pneumococcal vaccine services, 
suggesting the important role of rural 
pharmacies in vaccine access.   
To further assess the contribution of rural pharmacies to vaccine access, we assessed trends in pneumococcal 
vaccine delivery by provider type in rural and urban communities from 2012 to 2015 (Figure 1). The 
proportion of pneumococcal vaccines provided by pharmacists in rural areas increased from 19.9% in 2012 to 
33.5% in 2015 but has only modestly increased in urban areas (20.4% to 22.6%). 
Table 1. Total Number of PPSV23 and PCV13 
Vaccination Services, in Thousands, 2012-2015 
Year PPSV23 PCV13 
2012 1,067 (97.7%)   25 (2.3%) 
2013 1,077 (92.3%)   90 (7.7%) 
2014 1,025 (66.9%)   507 (33.1%) 
2015  445 (8.4%) 4,852 (91.6%) 
Table 2. Number of Pneumococcal Vaccination Services by 
Provider Type and Rural-Urban Designation, in Thousands, 2015 
Provider 
Type 
Rural  
Vaccination 
Services 
Urban  
Vaccination 
Services 
Combined  
Vaccination Services 
Pharmacy 247 (33.5%) 
 
1,049 (22.7%) 1,296 (24.2%) 
Primary Care 465 (63.1%) 3,398 (73.6%) 3,863 (72.2%) 
Other 25  (3.4%) 168  (3.6%) 193  (3.6%) 
Total 737   4,615   5,353  (100%) 
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Figure 1. Percent of Pneumococcal Vaccination Services Delivered by 
Provider Type and Rural-Urban Designation, 2012 to 2015 
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In 2015, pneumococcal vaccination service rates among FFS beneficiaries varied by state and ranged from 8% 
in Maine to 26% in Colorado (Figure 2, right panel). In comparison, the range during 2014 was 1% to 6% 
(Figure 2, left panel). Although overall pneumococcal vaccination rates in the FFS Medicare population have 
increased, a widening gap between highest and lowest vaccination rates in states (5% in 2014 vs 18% in 2015) 
is noted. Further county-level pneumococcal vaccinating service visualizations are available at our website: 
https://ruhrc.uky.edu/infographics/. 
 
Figure 2. Rate of Pneumococcal Vaccine Service Delivery per Eligible Population, 2014-2015  
 
 2014 (scale:1.1%-6.3%) 2015 (scale:7.7%-25.7%) 
 
Logistic regression indicates that increasing age of beneficiaries, greater proportion of female beneficiaries, and 
greater proportion of white non-Hispanic beneficiaries were positively associated with uptake of pneumococcal 
vaccine services, while rurality, greater use of outpatient services, and lower overall health status were 
negatively associated with uptake of pneumococcal vaccine services. The interaction between rurality and 
percent of vaccines provided by pharmacists was significant (P < .0001), and when interpreted with the finding 
from Figure 1 that pharmacists provide a greater proportion of vaccines in rural versus urban areas, suggests 
that community pharmacies play an important role in access to pneumococcal vaccinations in rural areas.  
Conclusion/Discussion 
We assessed pneumococcal vaccination service records for FFS beneficiaries from 2012, the first year during 
which PCV13 was recommended for high-risk adults age 20 and older, through 2015, the first full year during 
which PCV13 was recommended for all adults 65 and older. Among FFS beneficiaries from 2012 to 2015, the 
number of pneumococcal vaccination services increased greatly, and providers shifted from principally 
administering PPSV23 to PCV13. We estimate that in 2015, 16% of FFS beneficiaries received pneumococcal 
vaccination, with 92% administered PCV13. During years prior to 2015, there were lower rates of 
pneumococcal vaccination and much less frequent use of PCV13. Therefore, as of 2015, the majority of FFS 
beneficiaries remained to be vaccinated with PCV13 and it is likely pneumococcal vaccination services after 
2015 will remain elevated. Overall, rural areas experienced a lower rate of pneumococcal vaccination, and 
primary care providers were the most frequent contributors to pneumococcal vaccination. As primary care 
shortages in rural areas continue to grow, however, pharmacists appear to play an increasing role in providing 
vaccines in rural areas and have consistent importance in urban areas.  
In summary, following recommendations for administration of PCV13 to all adults 65 and older in September 
2014, pneumococcal vaccination rates increased almost 4-fold between 2014 and 2015. Continued disparities in 
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pneumococcal vaccination rates between rural and urban areas are noted, with community pharmacies serving 
as an important access point for pneumococcal vaccine services in rural communities. Given that the population 
of rural areas has a greater proportion of older adults than urban areas,8 continued support of rural service 
providers, including both primary care providers and pharmacists, is needed to ensure older adults have access 
to recommended vaccines.   
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